Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

25.74 +0.20 (+0.78%)

Delayed Quote Updated: 10:59 AM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

7 Biotech Stocks to Buy on the Dip: June 2024 ↗

June 24, 2024

With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.

Via InvestorPlace

Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts

June 18, 2024

These 2 small cap healthcare stocks could boom on a new sector breakout, Wall Street analysts see up to double-digit upside in each

Via MarketBeat

Topics ETFs Economy

Why the growth investor may take a look at NASDAQ:AMPH. ↗

June 05, 2024

AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) may be suited for growth investing, we'll explore why in this article.

Via Chartmill

Amphastar Announces Additional $50 Million Increase to its Share Buyback Program

June 04, 2024

Via ACCESSWIRE

Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

June 03, 2024

Via ACCESSWIRE

Exploring NASDAQ:AMPH's growth characteristics. ↗

May 15, 2024

AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) showing high EPS and FCF growth while beating expectations

Via Chartmill

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024

May 08, 2024

Via ACCESSWIRE

NASDAQ:AMPH, an undervalued stock with good fundamentals. ↗

March 12, 2024

AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH): good value for what you're paying.

Via Chartmill

Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol

May 22, 2024

Via ACCESSWIRE

Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade ↗

May 16, 2024

The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.

Via InvestorPlace

Topics Intellectual Property

Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference

May 09, 2024

Via ACCESSWIRE

AMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024 ↗

May 08, 2024

AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca ↗

May 01, 2024

The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic...

Via Benzinga

Topics Intellectual Property

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023

February 28, 2024

Via ACCESSWIRE

Delving into NASDAQ:AMPH's Growth Prospects. ↗

February 28, 2024

Should you consider AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) for growth investing?

Via Chartmill

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024

April 30, 2024

Via ACCESSWIRE

Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies ↗

April 10, 2024

Amphastar Pharmaceuticals discusses the future of Baqsimi at the Needham Healthcare Conference, highlighting its potential amid a growing market for glucagon products. With promising sales projections...

Via Benzinga

Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference

April 01, 2024

Via ACCESSWIRE

Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference

March 06, 2024

Via ACCESSWIRE

Earnings Outlook For Amphastar Pharma ↗

February 27, 2024

Via Benzinga

Is NASDAQ:AMPH a Fit for Growth Investing Strategies? ↗

February 14, 2024

Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing?

Via Chartmill

Is NASDAQ:AMPH a Fit for Growth Investing Strategies? ↗

February 07, 2024

Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock.

Via Chartmill

Unlocking the Growth Potential of NASDAQ:AMPH. ↗

January 23, 2024

Exploring AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH)'s growth characteristics.

Via Chartmill

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024

February 20, 2024

Via ACCESSWIRE

CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+ ↗

February 13, 2024

CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential ↗

February 05, 2024

As the new business cycle gets started, here are some biotech stocks with potential that investors should pay attention to.

Via InvestorPlace

Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating ↗

January 23, 2024

Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

Despite its impressive fundamentals, NASDAQ:AMPH remains undervalued. ↗

January 23, 2024

For those who appreciate value investing, AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) is a compelling option with its solid fundamentals.

Via Chartmill

What Vitamins Did For Healthy Living, Stemtech Corporation (OTCQB: STEK) Says It Is Doing For Anti-Aging With Stem Cell Nutrition ↗

January 19, 2024

Vitamins may not be a miracle cure, but combined with exercise and a healthy diet, they have the potential to greatly improve health and wellness. It’s no wonder vitamin supplements are a multi-billion...

Via Benzinga

Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive' ↗

January 17, 2024

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here.

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.